Hookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short Interest

Hookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 333,400 shares, an increase of 11.3% from the February 29th total of 299,500 shares. Approximately 0.6% of the company's stock are sold short. Based on an average daily volume of 2,410,000 shares, the days-to-cover ratio is presently 0.1 days.

Hookipa Pharma Price Performance

NASDAQ:HOOK traded up $0.01 on Monday, reaching $0.72. The stock had a trading volume of 223,562 shares, compared to its average volume of 553,125. The company has a market cap of $60.74 million, a price-to-earnings ratio of -0.82 and a beta of 1.03. The firm's fifty day moving average is $0.70 and its two-hundred day moving average is $0.63. Hookipa Pharma has a 12-month low of $0.41 and a 12-month high of $2.05.

Analyst Ratings Changes

HOOK has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $6.50 price target on shares of Hookipa Pharma in a research note on Monday, March 25th. Royal Bank of Canada reiterated an "outperform" rating and issued a $5.00 price target on shares of Hookipa Pharma in a research report on Monday, March 25th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in Hookipa Pharma by 1.2% in the first quarter. Bank of America Corp DE now owns 429,535 shares of the company's stock valued at $316,000 after buying an additional 5,199 shares during the period. State Street Corp raised its holdings in Hookipa Pharma by 18.5% in the second quarter. State Street Corp now owns 169,174 shares of the company's stock valued at $149,000 after buying an additional 26,367 shares during the period. Royal Bank of Canada raised its holdings in Hookipa Pharma by 10.8% in the third quarter. Royal Bank of Canada now owns 290,956 shares of the company's stock valued at $390,000 after buying an additional 28,263 shares during the period. Virtu Financial LLC purchased a new position in Hookipa Pharma in the second quarter valued at approximately $47,000. Finally, Mirabella Financial Services LLP acquired a new stake in Hookipa Pharma in the first quarter valued at approximately $82,000. 63.88% of the stock is currently owned by hedge funds and other institutional investors.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.